Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue

AIDS Research and Human Retroviruses

Volumn 29, Issue 11, 2013, Pages 1443-1450

  Louissaint, Nicolette A ^a   Cao, Ying Jun ^a   Skipper, Paul L ^b   Liberman, Rosa G ^b   Tannenbaum, Steven R ^b   Nimmagadda, Sridhar ^a   Anderson, Jean R ^a   Everts, Stephanie ^a   Bakshi, Rahul ^a   Fuchs, Edward J ^a   Hendrix, Craig W ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; TENOFOVIR DISOPROXIL;

ARTICLE; CD4+ T LYMPHOCYTE; COLON; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE HOMOGENATE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VAGINA;

ADENINE; ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; CARBON RADIOISOTOPES; COLON; FEMALE; HUMANS; ISOTOPE LABELING; LEUKOCYTES, MONONUCLEAR; ORGANOPHOSPHONATES; PLASMA; VAGINA;

EID: 84886705161     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0044     Document Type: Article

References (21)

1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al.: Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367: 399-401.
2. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al.: Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367: 423-434.
3. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al.: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363: 2587-2599.
4. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, et al.: Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367: 411-422.
5. MTN: MTN Statement on Decision to Discontinue Use of Oral Tenofovir Tablets in VOICE, a Major HIV Prevention Study in Women. Network MT, Web site article, 2011.
6. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-1174.
7. Hendrix CW: The clinical pharmacology of antiretrovirals for HIV prevention. Curr Opin HIV AIDS 2012; 7: 498-504.
8. Vogel JS and Turteltaub KW: Accelerator mass spectrometry as a bioanalytical tool for nutritional research. Adv Exp Med Biol 1998; 445: 397-410.
9. Louissaint NA, Nimmagadda S, Fuchs EJ, Bakshi RP, Cao YJ, et al.: Distribution of cell-free and cell-associated HIV surrogates in the colon after simulated receptive anal intercourse in men who have sex with men. J Acquir Immune Defic Syndr 2012; 59: 10-17.
10. Fuchs EJ, Lee LA, Torbenson MS, Parsons TL, Bakshi RP, et al.: Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: Potential implication for HIV transmission. J Infect Dis 2007; 195: 703-710.
11. Louissaint NA, Fuchs EJ, Bakshi RP, Nimmagadda S, Du Y, et al.: Distribution of cell-free and cell-associated HIV surrogates in the female genital tract after simulated vaginal intercourse. J Infect Dis 2012; 205: 725-732.
12. Watanabe K, Liberman RG, Skipper PL, Tannenbaum SR, and Guengerich FP: Analysis of DNA adducts formed in vivo in rats and mice from 1, 2-dibromoethane, 1, 2-dichloroethane, dibromomethane, and dichloromethane using HPLC/accelerator mass spectrometry and relevance to risk estimates. Chem Res Toxicol 2007; 20: 1594-1600.
13. Hillier SM, Marquis JC, Zayas B, Wishnok JS, Liberman RG, et al.: DNA adducts formed by a novel antitumor agent 11beta-dichloro in vitro and in vivo. Mol Cancer Ther 2006; 5: 977-984.
14. Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, et al.: MTN-001: Randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLOS One 2013; 8: e55013.
15. King T, Bushman L, Kiser J, Anderson PL, Ray M, et al.: Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 843: 147-156.
16. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, et al.: Penetration of tenofovir and emtricitabine in mucosal tissues: Implications for prevention of HIV-1 transmission. Sci Transl Med 2011; 3: 112re114.
17. Hawkins T, Veikley W, St Claire RL 3rd, Guyer B, Clark N, et al.: Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 2005; 39: 406-411.
18. Pruvost A, Negredo E, Benech H, Theodoro F, Puig J, et al.: Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2005; 49: 1907-1914.
19. Pruvost A, Negredo E, Theodoro F, Puig J, Levi M, et al.: Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): Investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother 2009; 53: 1937-1943.
20. Chen J, Flexner C, Liberman RG, Skipper PL, Louissaint NA, et al.: Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study. J Acquir Immune Defic Syndr 2012; 61: 593-599.
21. Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, et al.: Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008; 5: e28.